Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Munder, Markus
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Goldschmidt H
,
Mai EK
,
Bertsch U
,
Fenk R
,
Nievergall E
,
Tichy D
,
Besemer B
,
Dürig J
,
Schroers R
,
von Metzler I
, et al.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase
. Lancet Haematol. 2022;9(11):e810-e821.
PubMed
Google Scholar
C
Salwender H
,
Weinhold N
,
Benner A
,
Miah K
,
Merz M
,
Haenel M
,
Jehn C
,
Mai E
,
Menis E
,
Blau I
, et al.
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Hematology. 2024;29(1):2320006.
PubMed
Google Scholar
D
Palumbo A
,
Chanan-Khan A
,
Weisel K
,
Nooka AK
,
Masszi T
,
Beksac M
,
Spicka I
,
Hungria V
,
Munder M
,
Mateos MV
, et al.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016;375(8):754-766.
PubMed
Google Scholar
E
Mai EK
,
Goldschmid H
,
Miah K
,
Bertsch U
,
Besemer B
,
Hänel M
,
Krzykalla J
,
Fenk R
,
Schlenzka J
,
Munder M
, et al.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol. 2024;11(2):e101-e113.
PubMed
Google Scholar
O
Sonneveld P
,
Chanan-Khan A
,
Weisel K
,
Nooka AK
,
Masszi T
,
Beksac M
,
Spicka I
,
Hungria V
,
Munder M
,
Mateos M-V
, et al.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol. 2022:JCO2102734.
PubMed
Google Scholar